T4580
Tiludronate disodium salt hydrate
≥98% (HPLC)
别名:
Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C7H7ClNa2O6P2S · xH2O
CAS号:
分子量:
362.57 (anhydrous basis)
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to off-white
溶解性
H2O: >10 mg/mL, clear
创始人
Sanofi Aventis
SMILES字符串
O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O
InChI
1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2
InChI key
SZVJRJRMQCKFON-UHFFFAOYSA-L
生化/生理作用
Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.
特点和优势
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
制备说明
Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
C Delguste et al.
Journal of veterinary pharmacology and therapeutics, 31(2), 108-116 (2008-03-01)
Bioavailability and pharmacological effects of tiludronate were compared when administered as an intravenous (i.v.) bolus at a dosage of 0.1 mg/kg body weight (b.w.) once daily for 10 consecutive days (group 1, n = 6) and as a single constant
C Delguste et al.
Bone, 41(3), 414-421 (2007-07-03)
Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental
L Alvarez et al.
Rheumatology (Oxford, England), 43(7), 869-874 (2004-04-01)
To monitor the long-term evolution of Paget's disease activity after treatment with tiludronate by using serum total alkaline phosphatase (TAP) and more sensitive markers such as bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking
Virginie Coudry et al.
American journal of veterinary research, 68(3), 329-337 (2007-03-03)
To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. 29 horses with clinical manifestations of pain associated with lesions of the thoracolumbar vertebral column and abnormal
Peter Alexandersen et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 20(4), 588-595 (2005-03-15)
A new resorption assay measuring non-isomerized collagen type I C-telopeptide fragments (alpha-alpha CTX) was evaluated in a cohort comprising 32 Pagetic patients and 48 healthy controls. alpha-alpha CTX was found to be a sensitive marker for assessing disease activity and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门